Sandoz launches ustekinumab biosimilar in Europe
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
Sandoz has announced the European launch of Pyzchiva, a ustekinumab biosimilar approved for the treatment of several autoimmune conditions including…
Almirall has reported a 6.7% increase in total net sales for the first half of 2024, with the company’s European…
England’s National Institute for Health and Care Excellence (NICE) has recommended Almirall’s Ebglyss (lebrikizumab) for patients with moderate to severe…
The European Medicines Agency (EMA) has validated Philogen and Sun Pharmaceutical’s marketing authorisation application (MAA) for Nidlegy, a treatment for…
The US Food and Drug Administration (FDA) has approved the expanded use area for Almirall’s drug Klisyri (tirbanibulin) to up…
Philogen and Sun Pharmaceutical (Sun Pharma) have announced the filing of a marketing authorisation application (MAA) with the European Medicines…
ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis…
The China National Medical Products Administration (NMPA) has approved KeChow Pharma's tunlametinib (HL-085) for treating patients with neuroblastoma ras viral…
Almirall has signed an exclusive licence agreement to gain worldwide rights for Eloxx Pharmaceuticals’ ZKN-013 for rare dermatological disease indications.…